ABSTRACT
Fab fragments 12, 13 FcεRI see high-affinity IgE
receptors FcεRII 15-16 food allergies 6, 9, 31, 57
genetic factors 19
hay fever see allergic rhinitis helper T-cells 18, 22, 24
and anti-IgE 37 high-affinity IgE receptors
13-15, 21, 24 and anti-IgE 37, 38, 39-40, 56
histamine 26-7, 35, 41 house dust mite-induced
rhinitis 51-2 humanization of MAb 38 humanized anti-IgE MAb 39,
40, 56 hyper-IgE syndrome 58 hyper-reactivity, airway 28 hyper-responsiveness,
bronchial 2, 4, 29, 45
IgE 11-17, 28-30
18-23 IgE antibodies see anti-Ige
antibodies IgE-mediated allergic
disorders 6 IgM 43 immune response to
anti-IgE 43, 52-3 immunochemotherapy 51 immunoglobulin E see IgE immunoglobulin heavy
chain locus 21 immunosuppressive
drugs 34 immunotherapy 31, 51, 57 inflammatory activators
16 insect venom allergy 31 interferon 18 interleukins 18
IL-13 20, 22, 24 IL-4 20, 22, 24, 27 IL-4 antagonists 37 IL-4 antibody neutralization
37 IL-5 27
International Study of Asthma and Allergy in Childhood 7
intrinsic asthma 56-7 ipratropium bromide
34-5, 36
with anti-IgE 37 with omalizumab 45, 56
latex allergy 31 leukotrienes 27, 34
see also anti-leukotriene agents
loratidine 36 low-affinity IgE receptors
15-16, 21-3, 24 and anti-IgE 37, 39-40
lung function 47 lung function tests 3 lymphocytes 27
see also B-cells; helper T-cells
MAb see under anti-IgE antibodies
major histocompatibility complex 19, 20
management, current 31-6 mast cells
and allergic inflammation 26, 27
in chronic inflammation 28
effect of anti-IgE 37, 38, 39
IgE binding 13 mediators, inflammatory
15-16, 26, 27, 35 methacholine 44, 45 methotrexate 34
see under antibodies
mucous secretion 4-5
National Heart Lung and Blood Institute (NHLBI) 1
nedocromil sodium 34, 36 nematode infections 58 neutrophils 27 NHLBI see National Heart
Lung and Blood Institute NHLBI/WHO expert panel
report 1, 32 non-atopic asthma 56-7
omalizumab 39 in allergic rhinitis 51-5 in asthma 56
phase II trials 44-6 phase III trials 46-9
pharmacokinetics/ pharmacodynamics 41-2
pharmacology 40-1 safety/tolerability 42-3
in allergic rhinitis 52-3, 55 in asthma 49-50
subcutaneous route 46, 59 omalizumab-IgE complexes
41-2
P-K characteristics 42 P-K reaction 11, 12 paediatric patients see children parasitic infections 43, 58
pharmacodynamics 41-2 pharmacology 40-1 pharmacotherapy 31
allergic rhinoconjunctivitis 35-6
asthma 32-5 polyclonal antibodies 37, 43 prednisolone 33-4 prevalence of allergy/asthma
7-9, 29 proof-of-concept studies 44 prophylactic medications 33-4
quality of life 8, 49, 53
ragweed antigen 40 ragweed-induced rhinitis 52-3 receptors, IgE 13-16 recombinant humanized
anti-IgE antibody see omalizumab
regulation of IgE 18-23 rescue medications 33, 47, 52,
53 rhinitis see allergic rhinitis rhuMAb-E25 see omalizumab
safety anti-IgE antibodies 58 omalizumab 42-3, 49-50,
52-3, 55 salbutamol 34
salmeterol 16 schistosomiasis 43 sensitization 6, 24-6, serum clearance 42 serum IgE levels 30
effect of anti-IgE 44, 47, 52, 53
skin prick test 6, 10, 30, 52, 56 sodium cromoglycate 34, 35,
36 spasmogens 16 STAT-6 inhibitors 37 steroid sparing effect 47-9 steroids 35
see also corticosteroids structure of IgE 12-13 synthesis of IgE 18-23
T-helper cells see helper T-cells
T-lymphocytes 27 therapeutic strategies 37-43 tissue distribution studies 42 tolerability 49-50, 53, 55 triggers, non-allergenic 31 tumour necrosing factors
18, 27 tyrosine kinases 23
urticaria 49-50, 52, 55
World Health Organization 1
xenogenic antibodies 38 Xolair see omalizumab
